Recent News

• 09.11.2025 - Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold
• 04.30.2025 - Intercept Announces Data to be Presented at Digestive Disease Week 2025
• 11.12.2024 - Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)
• 10.17.2024 - Intercept Provides Regulatory Update Regarding sNDA for OCALIVA
• 09.13.2024 - Company Statement on FDA Advisory Committee Meeting
• 09.06.2024 - Findings From COBALT Trial, Including External Control Arm, Published in The American Journal of Gastroenterology
• 09.06.2024 - Findings From COBALT Trial, Including External Control Arm, Published in The American Journal of Gastroenterology
• 06.05.2024 - Intercept Presents New Data on the Results of OCA-Bezafibrate Combination Therapy in PBC After Six Months of Treatment in Late-Breaking Poster Presentation at EASL Congress 2024
• 06.05.2024 - Intercept Presents New Data on the Results of OCA-Bezafibrate Combination Therapy in PBC After Six Months of Treatment in Late-Breaking Poster Presentation at EASL Congress 2024
• 06.05.2024 - Intercept Presents New Data on the Results of OCA-Bezafibrate Combination Therapy in PBC After Six Months of Treatment in Late-Breaking Poster Presentation at EASL Congress 2024

Recent Filings